coteauBeta Get App
ASPI

ASPI

ASP Isotopes Inc.
$2.17
+6.90% Oct 21 close
Basic Materials Compare
1M3M6M1Y2Y
-80%-56%-31%-7%+17%Oct 2025Oct 2026Apr 2026
ASPISPY
1W
+4.8%
1M
-31.8%
3M
-46.8%
6M
-61.3%
YTD
-59.4%
1Y
-77.4%

Live chart

Loading live chart…

What they do

ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services.

Basic Materials · Specialty Chemicals

For information only · Important disclosures

Grades vs sector

No sector grades for ASPI yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Our models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
ASP Isotopes' Unit to Form Joint Venture With Nuclear Energy Corporation of South Africa
MT Newswires · Oct 15
RedChip to Host Virtual Investor Conference Showcasing the Next Generation of Energy Infrastructure on October 22
ACCESS Newswire · Oct 15
Quantum Leap Energy and Necsa Sign Binding Heads of Agreement to Establish Joint Venture for HALEU Production in South Africa
GlobeNewswire · Oct 15
ASP Isotopes Hosts Inaugural Capital Markets Day and Provides Operational Update
GlobeNewswire · Sep 08
ASP Isotopes Nears Helium Production, Advances Stable Isotope Growth
MarketBeat · Aug 21

Key stats

Market value$335.0M
P/E (next 12 months, estimated)-2.6
52-week range$1.89 – $11.22
Revenue growth (latest quarter vs a year ago)+327.6%
Dividend yieldNo dividend
Average analyst price target$13.00 (+499%)
Valuation and fundamentals

Valuation & fundamentals

Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score +0 (DCF counts double).
•Piotroski F-score5/9
▼Altman Z-0.1 (distress)
▲Analyst target+499% (3 analysts)

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 3.70 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Forward EPS $-0.83 vs trailing $-1.49. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin
18.3%
Operating margin
-321.1%
FCF margin
-270.9%
Net margin
-380.3%
Return on equity
-44.3%
Return on invested capital
-112.5%
Net debt / EBITDA
–
Current ratio
3.9×
Interest cover
-25.4×
Cash conversion (OCF/NI)
–
Piotroski F-score 5/9 · last two fiscal years
✗ Positive net income✗ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score -0.1 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target
$13
+499%
Analysts
3
None
Range
$11–$15
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$23.8M$-159.8M$-47.4M
2024$4.1M$-32.4M$-26.4M
2023$433.0K$-16.3M$-7.7M
2022$0$-4.9M$-7.4M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.

Earnings

Next report: 2026-11-12 · during market · EPS est -0.13
24-1125-0325-0525-0825-1126-0426-0526-08-1.030.00
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-08-14-0.31-0.25+18.5%
2026-05-20-0.28-0.05+82.1%
2026-04-10-0.14-0.41-200.0%
2025-11-19-0.10-0.15-50.0%
2025-08-14-0.11-1.03-836.4%
2025-05-20-0.10-0.12-20.0%
2025-03-31-0.09-0.13-44.4%
2024-11-19-0.09-0.12-33.3%

Quarterly revenue

QuarterRevenueYoY
2026-06-30$5.1M+327.6%
2026-03-31$4.2M–
2025-12-31$16.7M–
2025-09-30$4.9M–
2025-06-30$1.2M–
Analyst actions
Canaccord Genuity
2026-04-14 · main
Buy → Buy
PT $11
Cantor Fitzgerald
2025-12-04 · init
 → Overweight
PT $13
Canaccord Genuity
2025-11-24 · main
Buy → Buy
PT $11
Canaccord Genuity
2025-09-17 · main
Buy → Buy
PT $11
Canaccord Genuity
2025-05-21 · main
Buy → Buy
PT $11
Canaccord Genuity
2024-10-18 · main
Buy → Buy
PT $4
Insider trades
Ainscow Robert
COO · 2026-10-14-05:00
Sell
$47.6K
Ryan Robert John Andrew
Director · 2026-09-30-05:00
Buy
$40.2K
Ryan Robert John Andrew
Director · 2026-09-28-05:00
Buy
$21.6K
Ainscow Robert
COO · 2026-09-08-05:00
Sell
$36.2K
Mann Paul Elliot
Director, Chairman and CEO · 2026-09-04-05:00
Sell
$343.4K
Mann Paul Elliot
Director, Chairman and CEO · 2026-09-03-05:00
Sell
$328.3K
Mann Paul Elliot
Director, Chairman and CEO · 2026-09-02-05:00
Sell
$327.5K
Ainscow Robert
COO · 2026-09-02-05:00
Sell
$97.6K
Ainscow Donald George
EVP, Gen Counsel, Secretary · 2026-09-02-05:00
Sell
$92.1K

Stats refreshed 2026-10-21 11:25:02 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app

Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.

How it worksDisclaimerTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026